Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet

Volumn 381, Issue 9882, 2013, Pages 2024-2032

  Zhu, Feng Cai ^a,b   Meng, Fan Yue ^a   Li, Jing Xin ^a,b   Li, Xiu Ling ^c   Mao, Qun Ying ^d   Tao, Hong ^a   Zhang, Yun Tao ^c   Yao, Xin ^d   Chu, Kai ^a   Chen, Qing Hua ^c   Hu, Yue Mei ^a   Wu, Xing ^d   Liu, Pei ^e   Zhu, Lin Yang ^f   Gao, Fan ^d   Jin, Hui ^e   Chen, Yi Juan ^e   Dong, Yu Ying ^e   Liang, Yong Chun ^g   Shi, Nian Min ^h   Ge, Heng Ming ⁱ   Liu, Lin ^j   Chen, Sheng Gen ^g   Ai, Xing ^h   Zhang, Zhen Yu ⁱ   Ji, Yu Guo ^g   Luo, Feng Ji ^h   Chen, Xiao Qin ⁱ   Zhang, Ya ^j   Zhu, Li Wen ^g   Liang, Zheng Lun ^d   Shen, Xin Liang ^c   more..

^a JIANGSU PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c Sanjianfangnanli ^*  (China)

^d NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

^e SOUTHEAST UNIVERSITY   (China)

^f Department of Chronic Communicable Disease   (China)

^g Baoying County Center for Disease Control and Prevention   (China)

^h CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

ⁱ Donghai County Center for Disease Control and Prevention   (China)

^j Pizhou County Center for Disease Control and Prevention   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VACCINE; PLACEBO; VIRUS VACCINE;

CHILD; CHINA; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; ENTEROVIRUS 71; ENTEROVIRUS INFECTION; FATIGUE; FEEDING DISORDER; FEMALE; HAND FOOT AND MOUTH DISEASE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGY; INFANT; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; MALE; MORTALITY; MULTICENTER STUDY; NAUSEA; PATHOLOGICAL CRYING; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; VOMITING;

EID: 84878653325     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)61049-1     Document Type: Article

References (29)

1. Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 2010; 10: 778-90.
2. Jee YM, Cheon DS, Kim K, et al. Genetic analysis of the VP1 region of human enterovirus 71 strains isolated in Korea during 2000. Arch Virol 2003; 148: 1735-46.
3. Ho M. Enterovirus 71: the virus, its infections and outbreaks. J Microbiol Immunol Infect 2000; 33: 205-16.
4. Weng KF, Chen LL, Huang PN, Shih SR. Neural pathogenesis of enterovirus 71 infection. Microbes Infect 2010; 12: 505-10.
5. Zhu FC, Liang ZL, Li XL, et al. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet 2013. published online March 23. http://dx.doi.org/10.1016/S0140-6736(12)61764-4.
6. WHO. A guide to clinical management and public health response for hand, foot and mouth disease (HFMD). Geneva, Switzerland: World Health Organization, 2011. http://www.wpro.who.int/publications/docs/ GuidancefortheclinicalmanagementofHFMD.pdf (accessed Sept 28, 2012).
7. Lum LCS, Wong KT, Lam SK, Chua KB, Goh AYT. Neurogenic pulmonary oedema and enterovirus 71 encephalomyelitis. Lancet 1998; 352: 1391.
8. Chang L-Y, Lin T-Y, Hsu K-H, et al. Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease. Lancet 1999; 354: 1682-86.
9. Xu J, Qian Y, Wang S, et al. EV71: an emerging infectious disease vaccine target in the Far East? Vaccine 2010; 28: 3516-21.
10. Qiu J. Enterovirus 71 infection: a new threat to global public health? Lancet Neurol 2008; 7: 868-69.
11. Meng F Y, Li JX, Li XL, et al. Tolerability and immunogenicity of an inactivated enterovirus 71 vaccine in Chinese healthy adults and children: An open label, phase 1 clinical trial. Hum Vaccin Immunother 2012; 8: 668-74.
12. Zhu FC, Wang JZ, Li XL, et al. Reactogenicity and Immunogenicity of an Enterovirus 71 Vaccine in Chinese Healthy Children and Infants. Pediatric Infect Dis J 2012; 31: 1158-65.
13. Ho M, Chen ER, Hsu KH, et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 1999; 341: 929-35.
14. Barrett PN, Berezuk G, Fritsch S, et al. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2011; 377: 751-59.
15. Robertson SE, Traverso HP, Drucker JA, et al. Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine. Lancet 1988; 1: 897-99.
16. WHO. Immunological Basis for Immunization - Module 6: Poliomyelitis. Geneva, Switzerland: World Health Organization, 1993. http://whqlibdoc.who.int/ hq/1993/WHO-EPI-GEN-93.16-mod6.pdf (assessed March 22, 2013).
17. Hu YF, Yang F, Du J, et al. Complete genome analysis of coxsackievirus A2, A4, A5, and A10 strains isolated from hand, foot, and mouth disease patients in China revealing frequent recombination of human enterovirus A. J Clin Microbiol 2011; 49: 2426-34.
18. Hu YF, Du J, Zhao R, Xue Y, Yang F, Jin Q. Complete genome sequence of a recombinant coxsackievirus B4 from a patient with a fatal case of hand, foot, and mouth disease in Guangxi, China. J Virol 2012; 86: 10901-02.
19. Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol 2010; 9: 1097-105.
20. Kennett ML, Birch CJ, Lewis FA, Yung AP, Locarnini SA, Gust ID. Enterovirus type 71 infection in Melbourne. Bull World Health Organ 1974; 51: 609-15.
21. Chang LY, Tsao KC, Hsia SH, et al. Transmission and clinical features of enterovirus 71 infections in household contacts in Taiwan. JAMA 2004; 291: 222-27.
22. Orenstein WA, Bernier RH, Hinman AR. Assessing vaccine efficacy in the field. Further observations. Epidemiol Rev 1988; 10: 212-41.
23. Lee MS, Tseng FC, Wang JR, Chi CY, Chong P, Su IJ. Challenges to licensure of enterovirus 71 vaccines. PLoS Negl Trop Dis 2012; 6: e1737.
24. Paul Y. Herd immunity and herd protection. Vaccine 2004; 22: 301-02.
25. Poland GA, Jacobson RM. The re-emergence of measles in developed countries: time to develop the next-generation measles vaccines? Vaccine 2012; 30: 103-04.
26. Dominguez A, Torner N, Castilla J, et al. Mumps vaccine effectiveness in highly immunized populations. Vaccine 2010; 28: 3567-70.
27. Legay F, Leveque N, Gacouin A, et al. Fatal coxsackievirus A-16 pneumonitis in adult. Emerg Infect Dis 2007; 13: 1084-86.
28. Chan LG, Parashar UD, Lye MS, et al. Deaths of children during an outbreak of hand, foot, and mouth disease in Sarawak, Malaysia: clinical and pathological characteristics of the disease. For the Outbreak Study Group. Clin Infect Dis 2000; 31: 678-83.
29. Chang LY, King CC, Hsu KH, et al. Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan. Pediatrics 2002; 109: e88.